Zagreb, Croatia (Hybrid)

📍Location: Croatia or Serbia
Optimapharm is a globally operating, leading, mid-sized, full-service CRO aiming to deliver new therapies to improve and save patients’ lives.
Optimapharm’ s key priorities are the well-being of our people, consistent quality delivery to our clients and healthy, sustainable growth.
With 26 strategically located offices, Optimapharm operates in 40+ countries, providing most optimal access to Patients and Investigators globally. Established nearly 20 years ago, we leverage our experience, stable project teams and collaborative, and flexible approach to secure a high level of repeat business, gain the trust of new customers and secure continued growth of the company.
We’re looking for a Business Controller to join our Finance team. You’ll own financial reporting, planning, and analysis for assigned countries and profit centers, providing insights that drive strategic decisions. You’ll also support process improvements, reporting standardization, and business initiatives across the organization.
This role offers the opportunity to turn financial data into actionable strategies and make a real impact in a fast-moving business environment. If you thrive on ownership and analysis, we’d love to meet you!
By joining our fast-growing and prosperous team, you will have an excellent opportunity for further personal growth and career development.
If you would be interested in joining the Optimapharm team, please send your CV and note that only shortlisted candidates who meet the requirements will be contacted for the further selection process.
Compensation is competitive and final offers will reflect each candidate’s experience, skills, and qualifications.
Disclaimer: Unsolicited CVs sent to Optimapharm (Talent Acquisition Team, Hiring Managers or any other OPT employee) by recruitment agencies will not be considered for this role. Optimapharm follows a direct sourcing strategy and collaborates exclusively with selected recruitment partners when external support is required.